Abstract
Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.
Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Volume: 11 Issue: 4
Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz and Debabrata Mukherjee
Affiliation:
Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.
Abstract: Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.
Export Options
About this article
Cite this article as:
Said Sarmad, Porres-Aguilar Mateo, Porres-Munoz Mateo and Mukherjee Debabrata, Eisenmenger Syndrome: Recent Advances in Pharmacotherapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (4) . https://dx.doi.org/10.2174/1871525712666140321095519
DOI https://dx.doi.org/10.2174/1871525712666140321095519 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets From the RB Tumor Suppressor to MCR Peptides
Protein & Peptide Letters Identification and Investigation of Chalcone Derivatives as Calcium Channel Blockers: Pharmacophore Modeling, Docking Studies, In vitro Screening, and 3D-QSAR Analysis
Current Computer-Aided Drug Design Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Editorial [Hot Topic: Novel Pharmacological Therapies for Cardiac Hypertrophy and Heart Failure (Executive Guest Editor: Peter M. Kang)]
Current Pharmaceutical Design Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Synthesis and Endothelin Receptor Binding Affinity of a Novel Class of 2-Substituted-4-aryl-3-quinolinecarboxylic Acid Derivatives
Medicinal Chemistry Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Evaluation of Thyroid Hormone Status in Children with Steroid Resistant Nephrotic Syndrome: A North India Study
Endocrine, Metabolic & Immune Disorders - Drug Targets A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran
Cardiovascular & Hematological Agents in Medicinal Chemistry Ectopic ATP Synthase in Endothelial Cells: A Novel Cardiovascular Therapeutic Target
Current Pharmaceutical Design Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Genetic and Environmental Determinants of Early Vascular Ageing (EVA)
Current Vascular Pharmacology Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry